CoChat

OLIE, ITCC-082: A Phase II Trial of Lenvatinib Plus Ifosfamide and Etoposide in Relapsed/Refractory Osteosarcoma

Open access
Gaspar, Nathalie, Campbell-Hewson, Quentin, Huang, Jie, Okpara, Chinyere E, Bautista, Francisco · 2021 · Future Oncology

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in a Phase II study in patients with relapsed/refractory osteosarcoma. This Phase II randomized controlled trial (OLIE) will assess whether the combination of lenvatinib + ifosfamide + etoposide is superior to ifosfamide + etoposide alone in children, adolescents and young adults with relapsed/refractory osteosarcoma. The primary end point is progression-free survival; secondary and exploratory end points include, but are not limited to, overall survival, objective response rate, safety and tolerability, pharmacokinetic characterization of lenvatinib in the combination treatment, quality of life and quantification of baseline unresectable lesions that are converted to resectable.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon-2021-0743

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC-ND · From the PDF
Image 2
CC-BY-NC-ND · From the PDF
Image 3
CC-BY-NC-ND · From the PDF
Figure 1 Mechanism of action of lenvatinib + ifosfamide + etoposide.
Figure 1 Mechanism of action of lenvatinib + ifosfamide + etoposide.CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF
Image 6
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 4

  1. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines R ). Bone Cancer. Version 1.2021. https://www.nccn.org/professionals/physician gls/pdf /bone.pdf
  2. Gangireddy M, Nookala V. Ifosfamide. In: StatPearls [Internet] StatPearls Publishing, Trasure Island, FL, USA (2020).
  3. Eisai Inc. Lenvima (lenvatinib) [prescribing information]. Eisai Inc., Woodcliff Lake, NJ, USA (2020).
  4. Eisai Inc.. U.S.A. receive priority review from FDA for Lenvima R (lenvatinib) plus Keytruda R (pembrolizumab) applications for advanced renal cell carcinoma and for advanced endometrial carcinoma: applications based on progression-free survival, overall survival, and objective response rate data from respective pivotal phase 3 trials [press release]. Eisai Inc., Tokyo, Japan (2021). https://www.eisai.com/news/2021/news202133.html

Cited by

See all 9

Metadata

Authors
Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E., & Bautista, F.
Affiliations
  • Institut Gustave Roussy (FR)
  • The Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK
  • Eisai (United States) (US)
  • Eisai (United Kingdom) (GB)
  • Hospital Infantil Universitario Niño Jesús (ES)
Corresponding author
Gaspar, Nathalie
Venue
Future Oncology
Published
2021-08-12
Volume
17
Issue
32
Pages
4249-4261
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W3190087163
Cited by
9
References
46
Citations by year
2025: 3 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 1
FWCI
0.97
Type
journal article
Language
en
Open access
Locations
  • Future Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
  • Eisai Inc.
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
lenvatinib, ifosfamide, etoposide, multikinase inhibitor, combination chemotherapy, progression-free survival, children, adolescents and young adults, pharmacokinetics, quality of life, resectability
MeSH terms
Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Etoposide, Humans, Ifosfamide, Middle Aged, Phenylurea Compounds, Quality of Life, Quinolines, Osteosarcoma, Protein Kinase Inhibitors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: OLIE, ITCC-082: A Phase II Trial of Lenvatinib Plus Ifosfamide and Etoposide in Relapsed/Refractory Osteosarcoma. https://app.cochat.ai/papers/10.2217/fon-2021-0743
The paper
Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E., & Bautista, F. (2021). OLIE, ITCC-082: A Phase II Trial of Lenvatinib Plus Ifosfamide and Etoposide in Relapsed/Refractory Osteosarcoma. Future Oncology. https://doi.org/10.2217/fon-2021-0743

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.